American Academy of Neurology
UCB presentation highlights impacts of epilepsy on daily life
The data underlines the consequences of disrupted sleep for patients and caregivers
UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency
TK2d is an extremely rare disease characterised by severe and progressive muscle weakness
EpilepsyMeds receives Highly Commended recognition at Excellence in Healthcare Partnership Awards 2026
EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome
The study demonstrated a sustained reduction in seizures for patients
Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App
Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.
Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App
Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...
UCB shares promising results for fenfluramine in ultra-rare form of epilepsy
CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births
UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials
Approximately 125 million people worldwide are affected by some form of psoriasis
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults
The inflammatory skin disease affects approximately one in every 100 people in the US
UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab
The drug showed benefits across key secondary endpoints, including tau accumulation
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
The inflammatory skin disease affects about 1% of the population in most studied countries